Edgar Filing: Aclaris Therapeutics, Inc. - Form 4

Aclaris Therapeutics, Inc. Form 4 December 22, 2015

.5												
									PPROVAL			
UNITED	STATES					NGE	COMMISSION	N OMB Number:	3235-028	37		
Check this box if no longer subject to Section 16. Form 4 or)5		
-	a) of the P	ublic U	tility Hol	ding Cor	npany	y Act	of 1935 or Section	·	. 0.	.5		
ises)												
s of Reporting A.		2. Issuer Name and Ticker or Trading Symbol					5. Relationship of Reporting Person(s) to Issuer					
				tics, Inc	. [AC	RS]	(Check all applicable)					
HERAPEU	TICS,	(Month/I	Day/Year)	ransaction			X Director Officer (giv below)					
					Applicable Line) _X_Form filed by C					One Reporting Person		
19355							Form filed by Person	More than One R	eporting			
State)	(Zip)	Tab	le I - Non-I	Derivative	Secur	ities A	cquired, Disposed	of, or Beneficia	lly Owned			
nsaction Date h/Day/Year)	Execution I any	Date, if	Code (Instr. 8)	nAcquired Disposed (Instr. 3, 4	(A) or of (D) 4 and 5 (A) or	5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	Form: Direct (D) or Indirect (I)	7. Nature of Indirect Beneficial Ownership (Instr. 4)			
	UNITED STATEM Filed pur Section 17(ses) of Reporting A. First) (1 HERAPEU ENWOOD I Street) 19355 State) nsaction Date	UNITED STATES STATEMENT OF Filed pursuant to S Section 17(a) of the F 30(h) of sess) of Reporting Person * A. First) (Middle) HERAPEUTICS, ENWOOD DRIVE, Atreet) 19355 Mate) (Zip) Isaction Date 2A. Deeme Execution I any	UNITED STATES SECUL Wa STATEMENT OF CHAN Filed pursuant to Section 1 Section 17(a) of the Public U 30(h) of the Ir Section 17(a) of the Public U 30(h) of the Ir Section 17(a) of the Public U 30(h) of the Ir 30(h) of the Ir	UNITED STATES SECURITIES A Washington, STATEMENT OF CHANGES IN SECUE Filed pursuant to Section 16(a) of th Section 17(a) of the Public Utility Hol 30(h) of the Investment (a) (b) of the Investment (b) (b) (c) (c) (c) (c) (c) (c) (c) (c) (c) (c	UNITED STATES SECURITIES AND EX Washington, D.C. 20 STATEMENT OF CHANGES IN BENEF SECURITIES Filed pursuant to Section 16(a) of the Securi Section 17(a) of the Public Utility Holding Cor 30(h) of the Investment Compar ess) of Reporting Person [*] A. Symbol Aclaris Therapeutics, Inc First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) HERAPEUTICS, 12/18/2015 ENWOOD DRIVE, Atreet) A. If Amendment, Date Origina Filed(Month/Day/Year) 19355 State) (Zip) Table I - Non-Derivative nsaction Date 2A. Deemed A. (Zip) State) (Zip) Table I - Non-Derivative Securit TransactionAcquired any Code Disposed (Month/Day/Year) (Instr. 8) (Instr. 3, 4)	UNITED STATES SECURITIES AND EXCHA Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIA SECURITIES Filed pursuant to Section 16(a) of the Securities E Section 17(a) of the Public Utility Holding Company 30(h) of the Investment Company Ac ses) of Reporting Person [±] A. 2. Issuer Name and Ticker or Tradin Symbol Aclaris Therapeutics, Inc. [AC First) (Middle) 3. Date of Earliest Transaction (Month/Day/Year) HERAPEUTICS, 12/18/2015 ENWOOD DRIVE, Atreet) 4. If Amendment, Date Original Filed(Month/Day/Year) 19355 State) (Zip) Table I - Non-Derivative Secur saction Date 2A. Deemed 3. 4. Securities h/Day/Year) Execution Date, if TransactionAcquired (A) or any Code Disposed of (D) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5 (A) or	UNITED STATES SECURITIES AND EXCHANGE Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OV SECURITIES Filed pursuant to Section 16(a) of the Securities Exchar section 17(a) of the Public Utility Holding Company Act 30(h) of the Investment Company Act of 19 ses) of Reporting Person [*] 2. Issuer Name and Ticker or Trading A. Symbol Aclaris Therapeutics, Inc. [ACRS] "irst (Middle) 3. Date of Earliest Transaction (Month/Day/Year) HERAPEUTICS, 12/18/2015 ENWOOD DRIVE, atreet 4. If Amendment, Date Original Filed(Month/Day/Year) 19355 atate (Zip) Table I - Non-Derivative Securities A saction Date 2A. Deemed 3. 4. Securities h/Day/Year) Execution Date, if TransactionAcquired (A) or any Code Disposed of (D) (Month/Day/Year) (Instr. 8) (Instr. 3, 4 and 5)	UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 ses) of Reporting Person 1 2. Issuer Name and Ticker or Trading A. Symbol Aclaris Therapeutics, Inc. [ACRS] Work (Middle) 3. Date of Earliest Transaction (Month/Day/Year) Director HERAPEUTICS, 12/18/2015 Officer (give Differ (give NWOOD DRIVE, Table I - Non-Derivative Securities Acquired, Disposed of h/Day/Year) Code Disposed of (D) state) (Zip) Table I - Non-Derivative Securities Acquired, Disposed of h/Day/Year) Code S. Amount of Securities A and 5) Owned Following Reported Transaction(s) or (Instr. 3, 4 and 5) Owned (A) Transaction(s) or (Instr. 3 and 4)	OMB A OMB A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB Number: Expires: STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Expires: Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 ses) of Reporting Person [±] 2. Issuer Name and Ticker or Trading A. S. Relationship of Reporting Per Issuer A. Claris Therapeutics, Inc. [ACRS] (Check all applicable instrimed to the function of the function of the public Utility Poly (Year) Image: Check all applicable (Month/Day/Year) HERAPEUTICS, ENWOOD DRIVE, 12/18/2015 Image: Check all applicable Line) -X_Form filed by One Reporting Per Image: Check all applicable Line) treet) 4. If Amendment, Date Original Filed(Month/Day/Year) 6. Individual or Joint/Group Fili Applicable Line) 19355 Table I - Non-Derivative Securities Acquired, Disposed of , Form: Direct any Governeting Person Mate) 2A. Deemed 3. 4. Securities Code 5. Amount of Disposed of (D) Barterio (Month/Day/Year) 3. 4. Securities Code 5. Amount of Disposed of (D) State (Clip) 3. 4. Securities Code 5. Amount of Disposed of (D) State (Clip) 3. 4. Securities Code 6. Ownership	OMB APPROVAL OMB APPROVAL OMB APPROVAL OMB APPROVAL STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 OMB 3235-028 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Expires: 200 SECURITIES Expires: 200 Securities Exchange Act of 1934, Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section 30(h) of the Investment Company Act of 1940 Section 200(h) of the Investment Company Act of 1940 Section 17(a) of the Public Utility Holding Company Act of 1935 or Section Aclaris Therapeutics, Inc. [ACRS] (Month/Day/Year) Section 16(a) of the Public Utility Holding Company Act of 1940 Section 200(h) of the Investment Company Act of 1940 Section 200 Section 200(h) of the Investment Company Act of 1940 Section 200(h)		

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4. 5. Number	6. Date Exercisable and	7. Title and Amount of	8. I
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transaction of Derivative	Expiration Date	Underlying Securities	Der

Edgar Filing: Aclaris Therapeutics, Inc. - Form 4

Security (Instr. 3)	or Exercise Price of Derivative Security		any (Month/Day/Year)	Code (Instr. 8	(Instr. 8) A (A D (I			(Month/Day/Year)		(Instr. 3 and 4)		Sec (Ins
				Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	
Stock option (right to buy)	\$ 28.68	12/18/2015		А		7,095		(1)	12/17/2025	Common Stock	7,095	

Reporting Owners

Reporting Owner Name / Address		Relationships				
	Director	10% Owner	Officer	Other		
Tullman Stephen A. C/O ACLARIS THERAPEUTICS, INC. 101 LINDENWOOD DRIVE, SUITE 40 MALVERN, PA 19355	0 X					
Signatures						
/s/ Brian F. Leaf, Attorney-in-fact	2/22/2015					
**Signature of Reporting Person	Date					

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) 25% of the shares underlying this option will vest on December 18, 2016 and the remaining shares vest in 36 equal monthly installments thereafter, subject to the reporting person's continued service with the issuer as of the applicable vesting date.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.